The Latest Breaking News from FDA

A new study using radioactive psychedelics suggests that infants who die of SIDS have abnormal serotonin receptors

U.S. health regulators have given full approval to Pfizer’s COVID-19 pill Paxlovid

It has contributed to an epidemic of drug deaths in the US

Endocrine disrupters and other potentially dangerous ingredients persist despite FDA concerns.

Medtronic is facing sluggish sales growth, is in the midst of deep cost-cutting and started ongoing global layoffs in April. It's also spinning off businesses with weaker profit margins.

WASHINGTON – Sen. John Cornyn earned a spot on Donald Trump’s naughty list by saying the GOP should pick someone else for president in 2024.

It is only the seventh case of the deadly disease reported in the U.S. since it first emerged in the country in 2003.

Coupled with the macroeconomic headwinds, the U.S. debt default crisis and consequent recessionary fears have triggered market volatility. Against this backdrop, quality growth stocks Boston Scientific (BSX), Cardinal Health (CAH), Cidara Therapeutics (CDTX), and Geospace Technologies (GEOS) could be solid buys now. Read on….

Karl Warburton, 43, died last May from xylazine, which is used by vets as a tranquilliser for large animals such as horses and cows - the drug has never been approved for human use as it can cause flesh-rotting sores on takers’ skin

Xylazine is a powerful sedative which has swept across the United States.

The FDA pushed back its review of a highly anticipated gene therapy from Sarepta Therapeutics on Wednesday, prompting SRPT stock to tumble.